SLDB
Solid Biosciences LLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$789.10M
P/E Ratio
—
EPS
$-1.99
Beta
2.58
52W High
$8.72
52W Low
$2.41
50-Day MA
$6.72
200-Day MA
$5.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Solid Biosciences LLC
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-96.43M |
| EBITDA | $-177.57M |
| Operating Margin | 0.00% |
| Return on Equity | -109.90% |
| Return on Assets | -53.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.28 |
| Price-to-Book | 4.09 |
| Price-to-Sales (TTM) | 3.65 |
| EV/Revenue | 1.156 |
| EV/EBITDA | -3.69 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $98.39M |
| Float | $63.05M |
| % Insiders | 0.73% |
| % Institutions | 83.45% |
Analyst Ratings
Consensus ($17.08 target)
4
Strong Buy9
BuyData last updated: 4/9/2026